These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26335105)

  • 1. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
    van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
    BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).
    van Roozendaal LM; Vane MLG; van Dalen T; van der Hage JA; Strobbe LJA; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; Van de Vijver KKBT; de Vries J; Westenberg AH; Kessels AGH; de Wilt JHW; Smidt ML
    BMC Cancer; 2017 Jul; 17(1):459. PubMed ID: 28668073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
    de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
    Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
    Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
    Andersson Y; Bergkvist L; Frisell J; de Boniface J
    Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
    Donker M; van Tienhoven G; Straver ME; Meijnen P; van de Velde CJ; Mansel RE; Cataliotti L; Westenberg AH; Klinkenbijl JH; Orzalesi L; Bouma WH; van der Mijle HC; Nieuwenhuijzen GA; Veltkamp SC; Slaets L; Duez NJ; de Graaf PW; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JW; Belkacemi Y; Petignat P; Schinagl DA; Coens C; Messina CG; Bogaerts J; Rutgers EJ
    Lancet Oncol; 2014 Nov; 15(12):1303-10. PubMed ID: 25439688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
    de Boniface J; Frisell J; Andersson Y; Bergkvist L; Ahlgren J; Rydén L; Olofsson Bagge R; Sund M; Johansson H; Lundstedt D;
    BMC Cancer; 2017 May; 17(1):379. PubMed ID: 28549453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial.
    Jung JG; Ahn SH; Lee S; Kim EK; Ryu JM; Park S; Lim W; Jung YS; Chung IY; Jeong J; Chang JH; Shin KH; Chang JM; Moon WK; Han W
    BMC Cancer; 2022 Feb; 22(1):189. PubMed ID: 35184724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes.
    Goyal A; Mann GB; Fallowfield L; Duley L; Reed M; Dodwell D; Coleman RE; Fakis A; Newcombe R; Jenkins V; Whitham D; Childs M; Whynes D; Keeley V; Ellis I; Fairbrother P; Sadiq S; Monson K; Montgomery A; Tan W; Vale L; Homer T; Badger H; Haines RH; Lewis M; Megias D; Nabi Z; Singh P; Caraman A; Miles E;
    BMJ Open; 2021 Dec; 11(12):e054365. PubMed ID: 34857578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of the axilla in breast cancer: evidences and unresolved issues].
    Fodor J; Polgár C; Péley G; Németh G
    Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
    Galimberti V; Cole BF; Zurrida S; Viale G; Luini A; Veronesi P; Baratella P; Chifu C; Sargenti M; Intra M; Gentilini O; Mastropasqua MG; Mazzarol G; Massarut S; Garbay JR; Zgajnar J; Galatius H; Recalcati A; Littlejohn D; Bamert M; Colleoni M; Price KN; Regan MM; Goldhirsch A; Coates AS; Gelber RD; Veronesi U;
    Lancet Oncol; 2013 Apr; 14(4):297-305. PubMed ID: 23491275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer.
    Sit D; Lalani N; Chan E; Tran E; Speers C; Gondara L; Chia S; Gelmon K; Lohrisch C; Nichol A
    Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):861-869. PubMed ID: 34762971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
    Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
    JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
    Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
    J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
    Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
    Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary node interventions in breast cancer: a systematic review.
    Rao R; Euhus D; Mayo HG; Balch C
    JAMA; 2013 Oct; 310(13):1385-94. PubMed ID: 24084924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.